LPTX LEAP THERAPEUTICS, INC.

Nasdaq leaptx.com


$ 1.55 $ 1.44 (237.96 %)    

Wednesday, 12-Nov-2025 19:59:58 EST
QQQ $ 607.01 $ -10.67 (-1.73 %)
DIA $ 474.62 $ -6.74 (-1.4 %)
SPY $ 670.94 $ -9.52 (-1.4 %)
TLT $ 89.47 $ -0.33 (-0.37 %)
GLD $ 382.84 $ -4.45 (-1.15 %)
$ 2.05
$ 0.61
$ 1.54 x 63
$ 1.56 x 180
-- - --
$ 0.22 - $ 3.61
760,562,526
na
116.14M
$ 1.49
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-12-2025 09-30-2025 10-Q
2 08-14-2025 06-30-2025 10-Q
3 05-13-2025 03-31-2025 10-Q
4 03-26-2025 12-31-2024 10-K
5 11-13-2024 09-30-2024 10-Q
6 08-12-2024 06-30-2024 10-Q
7 05-13-2024 03-31-2024 10-Q
8 03-18-2024 12-31-2023 10-K
9 11-13-2023 09-30-2023 10-Q
10 08-14-2023 06-30-2023 10-Q
11 05-15-2023 03-31-2023 10-Q
12 03-24-2023 12-31-2022 10-K
13 11-14-2022 09-30-2022 10-Q
14 08-12-2022 06-30-2022 10-Q
15 05-13-2022 03-31-2022 10-Q
16 03-11-2022 12-31-2021 10-K
17 11-12-2021 09-30-2021 10-Q
18 08-13-2021 06-30-2021 10-Q
19 05-14-2021 03-31-2021 10-Q
20 03-12-2021 12-31-2020 10-K
21 11-12-2020 09-30-2020 10-Q
22 08-13-2020 06-30-2020 10-Q
23 05-14-2020 03-31-2020 10-Q
24 03-16-2020 12-31-2019 10-K
25 11-14-2019 09-30-2019 10-Q
26 08-09-2019 06-30-2019 10-Q
27 05-15-2019 03-31-2019 10-Q
28 04-01-2019 12-31-2018 10-K
29 11-09-2018 09-30-2018 10-Q
30 08-08-2018 06-30-2018 10-Q
31 05-11-2018 03-31-2018 10-Q
32 02-23-2018 12-31-2017 10-K
33 11-13-2017 09-30-2017 10-Q
34 08-11-2017 06-30-2017 10-Q
35 05-12-2017 03-31-2017 10-Q
36 03-31-2017 12-31-2016 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 whats-going-on-with-leap-therapeutics-stock-on-thursday

Leap Therapeutics shares are plunging after rebranding as Cypherpunk, pivoting to a Zcash treasury and announcing a $200M stock...

 leap-therapeutics-q3-eps-008-beats-024-estimate

Leap Therapeutics (NASDAQ:LPTX) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0...

 leap-therapeutics-reports-final-results-from-part-b-of-defiance-study-phase-2-study-of-sirexatamab-in-mss-crc-patients-who-have-received-one-prior-systemic-therapy-for-advanced-disease

Sirexatamab demonstrated statistically significant improvement in PFS and OS in DKK1-high populationIncreasing DKK1 levels furt...

 why-is-leap-therapeutics-down-9-in-pre-market-trading

Leap Therapeutics is trading lower in pre-market following a $58.9 million private placement led by Winklevoss Capital.

 leap-therapeutics-secures-589m-pipe-led-by-winklevoss-capital-for-9585m-shares-and-warrants-to-buy-719m-shares

Leap Therapeutics (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION